BANK OF AMERICA CORP /DE/ - CTI BIOPHARMA CORP ownership

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q4 2016$0
-100.0%
75
-96.7%
0.00%
Q3 2016$1,000
-97.1%
2,286
-97.7%
0.00%
Q2 2016$34,000
+209.1%
100,213
+393.4%
0.00%
Q1 2016$11,000
-85.1%
20,309
-66.3%
0.00%
Q4 2015$74,000
+362.5%
60,182
+464.5%
0.00%
Q3 2015$16,000
-63.6%
10,662
-52.9%
0.00%
Q2 2015$44,000
+18.9%
22,635
+10.2%
0.00%
Q1 2015$37,000
-71.8%
20,540
-63.1%
0.00%
Q4 2014$131,000
+151.9%
55,611
+160.0%
0.00%
Q3 2014$52,000
-80.6%
21,386
-77.5%
0.00%
Q2 2014$268,00095,2350.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q1 2017
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,425,000$3,363,0002.66%
ACUTA CAPITAL PARTNERS, LLC 1,228,111$2,898,0001.96%
Sio Capital Management, LLC 505,000$1,192,0000.94%
RA Capital Management 2,500,000$5,900,0000.63%
SPHERA FUNDS MANAGEMENT LTD. 750,000$1,770,0000.30%
TFS CAPITAL LLC 1,295,744$3,058,0000.29%
EAGLE ASSET MANAGEMENT INC 12,713,051$30,002,0000.17%
JW Asset Management, LLC 52,271$123,0000.09%
Lombard Odier Asset Management (USA) Corp 501,444$1,183,0000.08%
First Heartland Consultants, Inc. 74,624$176,0000.07%
View complete list of CTI BIOPHARMA CORP shareholders